Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases

被引：21
作者：
Dahan, Laurie Saloner [1 ,2 ,3 ]
Giorgi, Roch [4 ]
Vergez, Sebastien [3 ,5 ]
de Gabory, Ludovic Le Taillandier [3 ,6 ]
Costes-Martineau, Valerie [3 ,7 ]
Herman, Philippe [3 ,8 ]
Poissonnet, Gilles [3 ,9 ]
Mauvais, Olivier [3 ,10 ]
Malard, Olivier [3 ,11 ]
Garrel, Renaud [3 ,12 ]
Uro-Coste, Emmanuelle [3 ,13 ]
Barry, Beatrix [3 ,14 ]
Bach, Christine [3 ,15 ]
Chevalier, Dominique [3 ,16 ]
Mouawad, Francois [3 ,16 ]
Merol, Jean-Claude [3 ,17 ]
Bastit, Vianney [3 ,18 ]
Thariat, Juliette [3 ,18 ]
Gilain, Laurent [3 ,19 ]
Dufour, Xavier [3 ,20 ]
Righini, Christian-Adrien [3 ,21 ]
Moya-Plana, Antoine [3 ,22 ]
Even, Caroline [3 ,22 ]
Radulesco, Thomas [1 ,2 ,3 ]
Michel, Justin [1 ,2 ,3 ]
Baujat, Bertrand [3 ,23 ,24 ]
Fakhry, Nicolas [1 ,2 ,3 ]
机构：
[1] Ctr Hosp Univ Conception, Serv ORL & Chirurg Cervicofaciale, 147 Blvd Baille, F-13005 Paris, France
[2] Aix Marseille Univ, Marseille, France
[3] REFCOR Reseau Expertise Francais Canc ORL Rares, Paris, France
[4] Aix Marseille Univ, Hop Timone, AP HM,BioST,Biostat & Technol Informat & Commun, INSERM,IRD,SESSTIM,Sci Econ & Sociales Sante & Tr, Marseille, France
[5] CHU Toulouse, Oncopole, Serv ORL & Chirurg Cervicofaciale, Toulouse, France
[6] CHU Bordeaux, Serv ORL & Chirurg Cervicofaciale, Bordeaux, France
[7] CHU Montpellier, Serv Anat Pathol, Montpellier, France
[8] Hop Lariboisiere, Assistance Publ Hop Paris, Serv ORL Chirurg Maxillofaciale & Plast, Paris, France
[9] Inst Univ Face & Cou, Serv ORL & Chirurg Cervicofaciale, Ctr Antoine Lacassagne, Nice, France
[10] CHU Besancon, Serv ORL, Audiophoniatrie, Chirurg Cervicofaciale, Besancon, France
[11] CHU Nantes, Serv ORL & Chirurg Cervicofaciale, Nantes, France
[12] CHU Montpellier, Serv ORL & Chirurg Cervicofaciale, Montpellier, France
[13] Inst Univ Canc Oncopole, Serv Anat & Cytol Pathol, Toulouse, France
[14] CHU Paris Nord Val Seine, Hop Xavier Bichat Claude Bernard, Assistance Publ Hop Paris, Serv ORL & Chirurg Cervicofaciale, Paris, France
[15] Hop Foch, Serv ORL & Chirurg Face & Cou, Suresnes, France
[16] CHU Lille, Serv ORL & Chirurg Cervicofaciale, Lille, France
[17] CHU Reims, Serv ORL & Chirurg Cervicofaciale, Reims, France
[18] Ctr Francois Baclesse, Serv ORL & Chirurg Cervicofaciale, Caen, France
[19] CHU Clermont Ferrand, Serv ORL & Chirurg Cervicofaciale, Clermont Ferrand, France
[20] CHU Poitiers, Serv ORL & Chirurg Cervicofaciale, Poitiers, France
[21] CHU Grenoble, Serv ORL & Chirurg Cervicofaciale, Grenoble, France
[22] Inst Gustave Roussy, Serv Oncol Med Tete & Cou, Villejuif, France
[23] Sorbonne Univ, Paris, France
[24] Hop Tenon, Assistance Publ Hop Paris, Serv ORL & Chirurg Cervicofaciale, Paris, France
来源：
EJSO | 2021年 / 47卷 / 06期
关键词：
Salivary glands; Cancer; Parotid gland; Mucoepidermoid carcinoma; CLINICAL-PATHOLOGICAL CORRELATION; PAROTID-GLAND; PROGNOSTIC-FACTORS; SURVIVAL; CANCER; MANAGEMENT; OUTCOMES; ORIGIN; CLASSIFICATION; EXPRESSION;
D O I：
10.1016/j.ejso.2020.11.123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: To describe the characteristics of the largest European study of MEC of salivary glands and to determine the prognostic factors for overall and disease free survival. Patients and methods: Patients with MEC were prospectively included in the Reseau d'Expertise Francais sur les Cancers ORL Rares (REFCOR, French Network of Rare Head and Neck Tumors) database between 2009 and 2015. Results: A total of 292 patients were included. Tumors were classified as low grade in 175 cases (60%), intermediate in 39 (13%) and high grade in 78 (27%). Median follow-up was 26 months. The 5-year OS and DFS rates were respectively 83% and 69%. In multivariate analysis, age (p = 0.004), diabetes (p = 0.02) and advanced stage (p = 0.03) were found to have a significant negative impact on OS. Diabetes (p = 0.001), alcohol consumption (p = 0.003) and advanced stage (p = 0.001) were found to have a significant negative impact on DFS. Compare to low grade, high grade tended to have a negative impact on OS (p = 0.05) and had a significant effect on DFS (0.002) while intermediate grade had no significant influence on survival. The surgical treatment had a positive impact on both OS (p = 0.00005) and DFS (p = 0.0005). Postoperative radiotherapy had no impact in multivariate analysis. Conclusion: Advanced clinical stage, high grade tumor, high age, the impossibility of carrying out a complete surgical resection, and diabetes are the main prognostic factors in this prospective series of patients with MEC. Such findings open new research perspectives on the influence of these components on initial patient care. (C) 2020 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码：1376 / 1383
页数：8
相关论文
共 47 条
  • [1] Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study
    Abd-Elhamid, Ehab S.
    Elmalahy, Mohamed H.
    [J]. DIAGNOSTIC PATHOLOGY, 2010, 5
  • [2] Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma Data From the National Cancer Data Base
    Amini, Arya
    Waxweiler, Timothy V.
    Brower, Jeffrey V.
    Jones, Bernard L.
    McDermott, Jessica D.
    Raben, David
    Ghosh, Debashis
    Bowles, Daniel W.
    Karam, Sana D.
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2016, 142 (11) : 1100 - 1110
  • [3] Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role
    Aquino, Gabriella
    Collina, Francesca
    Sabatino, Rocco
    Cerrone, Margherita
    Longo, Francesco
    Ionna, Franco
    Losito, Nunzia Simona
    De Cecio, Rossella
    Cantile, Monica
    Pannone, Giuseppe
    Botti, Gerardo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (02)
  • [4] Management and Outcome of Patients With Mucoepidermoid Carcinoma of Major Salivary Gland Origin: A Single Institution's 30-Year Experience
    Aro, Katri
    Leivo, Ilmo
    Makitie, Antti A.
    [J]. LARYNGOSCOPE, 2008, 118 (02) : 258 - 262
  • [5] AUCLAIR PL, 1992, CANCER, V69, P2021, DOI 10.1002/1097-0142(19920415)69:8<2021::AID-CNCR2820690803>3.0.CO
  • [6] 2-7
  • [7] Salivary Mucoepidermoid Carcinoma: A Multi-Institutional Review of 76 Patients
    Bai S.
    Clubwala R.
    Adler E.
    Sarta C.
    Schiff B.
    Smith R.V.
    Gnepp D.R.
    Brandwein-Gensler M.
    [J]. Head and Neck Pathology, 2013, 7 (2) : 105 - 112
  • [8] Barnes L., 2005, WHO Classification of Tumour, P163, DOI DOI 10.1016/J.UROLOGY.2004.09.048
  • [9] HISTOPATHOLOGIC GRADING OF SALIVARY-GLAND NEOPLASMS .1. MUCOEPIDERMOID CARCINOMAS
    BATSAKIS, JG
    LUNA, MA
    [J]. ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1990, 99 (10) : 835 - 838
  • [10] Mucoepidermoid carcinoma of the parotid gland - The Mayo Clinic experience
    Boahene, DKO
    Olsen, KD
    Lewis, JE
    Pinheiro, AD
    Pankratz, VS
    Bagniewski, SM
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2004, 130 (07) : 849 - 856
12345